Strategic alignment
AI priorities tied to explicit business outcomes.
Let's talk RISE Research
Help establish a clearer benchmark for what moves AI from experimentation to trusted, sustained and measurable enterprise value.
Why this study matters
Life sciences organizations are investing in AI, yet many initiatives struggle to progress from promising pilots to sustained operational use. The challenge spans strategy, decision rights, data, governance, workflow integration, trust and human adoption.
This study examines those conditions from both sides of the market: the enterprises adopting AI and the partners helping them do it.
The RISE Index™ is a research study, not the individual RISE AI Maturity Assessment™. The free assessment explores readiness across six capability dimensions; this study examines five enterprise-readiness dimensions and will report responses in aggregate.
Explore Enterprise AI Strategy + Adoption, use the RISE Executive Guide to AI vendor evaluation and adoption, read Curbside Consult 07, or listen to RISE Unpacked on why pharma pilots do not scale.
The RISE Index™ framework
The RISE Index™ will create a practical 0–100 benchmark across the conditions required to scale enterprise AI.
AI priorities tied to explicit business outcomes.
Clear stakeholders, decision rights and proof requirements.
Fit-for-purpose data, workflows and support capacity.
Early risk engagement, accountability and transparency.
Changed behavior reinforced by measurable outcomes.
Responses will be analyzed collectively. RISE will not attribute comments or identify participants or organizations without separate permission.
Screening questions ensure the benchmark reflects qualified leaders directly involved in enterprise AI decisions, governance, implementation or adoption.
The final report will identify adoption patterns, enterprise-provider expectation gaps and the priorities most likely to shape 2027.
Contribute your perspective
Qualified participants may request the executive findings and volunteer for a confidential follow-up conversation.
Begin the survey